Skip to main content
Virtual Event | Drug Patents and Evidence-Based Policymaking in Patent Law
Glass medicine bottles on a production line. (Getty Images)
Glass medicine bottles on a production line. (Getty Images)

Virtual Event | Drug Patents and Evidence-Based Policymaking in Patent Law

This event will premiere on this page at 10:00 a.m. EDT, Friday, April 15. Register for the event here.

Join Hudson Institute Senior Fellow Urška Petrovčič and expert panelists David Kappos, Erika Lietzan, and Senior Fellow Adam Mossoff for a discussion on the role of drug patents as a driver of innovation in healthcare and the importance of evidence-based policymaking in patent law.

Congress and federal agencies have been holding hearings, issuing reports, and considering various policy measures on whether drug patents raise prices in healthcare. These legislative and policy efforts have been driven by reports published by I-MAK of massively high numbers of patents on specific drugs. Yet as a recent Hudson Institute policy memo by Adam Mossoff explains, I-MAK’s patent numbers are unreliable and its private database is unverifiable. Please join our expert panel for a discussion on the policy debate over drug patents and the importance of evidence-based policymaking by Congress and agencies.

Speakers

David Kappos

Partner, Cravath, Swaine & Moore LLP, Former Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

Erika Lietzan

William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law, University of Missouri School of Law

Adam Mossoff

Chair, Forum for Intellectual Property, and Senior Fellow, Hudson Institute, and Professor of Law, Antonin Scalia Law School, George Mason University

Moderator

Urška Petrovčič

Senior Fellow, Hudson Institute

Hudson Experts

Related Events